Vistagen Therapeutics, INC 8-K filings

Vistagen Therapeutics reports positive results from a Phase 2A study of PH284 nasal spray, showing improved subjective feelings of hunger in cancer patients with cachexia.

Vistagen Therapeutics has commenced a repeat dose study of fasedienol, an investigational nasal spray, as part of its Phase 3 development program for social anxiety disorder.

Vistagen Therapeutics has released a new corporate presentation detailing its neuroscience pipeline, including updates on its Phase 3 program for Social Anxiety Disorder and other clinical programs.

Vistagen Therapeutics announced its fiscal year 2025 second quarter financial results, highlighted by the progression of its PALISADE Phase 3 program for fasedienol and the initiation of the PALISADE-4 trial.

Vistagen Therapeutics has commenced its PALISADE-4 Phase 3 trial for fasedienol, a nasal spray aimed at treating social anxiety disorder.

Vistagen Therapeutics held its 2024 Annual Meeting, where stockholders elected directors, approved executive compensation, and ratified the appointment of KPMG as the company's auditor.

Vistagen Therapeutics announced its fiscal year 2025 first quarter financial results, highlighting progress in its PALISADE Phase 3 program for social anxiety disorder and other pipeline developments.

Vistagen Therapeutics has changed its independent auditor from WithumSmith+Brown to KPMG, effective July 8, 2024, following a competitive selection process.

Vistagen Therapeutics has broadened its intellectual property portfolio with new patents for its PH80 nasal spray, intended for migraine treatment.

Vistagen Therapeutics has received the Mental Health America's Platinum Bell Seal for Workplace Mental Health for the second consecutive year, recognizing their commitment to employee well-being.

Vistagen Therapeutics announced its fiscal year 2024 financial results, highlighted by positive Phase 3 trial results for fasedienol in social anxiety disorder and progress in other pipeline programs.

Vistagen Therapeutics' stockholders approved amendments to the company's equity incentive plan and employee stock purchase plan at a special meeting on May 29, 2024.

Vistagen Therapeutics will present posters on its investigational pherine candidates, fasedienol and itruvone, at the American Society of Clinical Psychopharmacology Conference in Miami Beach, Florida.

Vistagen's PH15 nasal spray demonstrated statistically significant improvement in reaction time compared to placebo and caffeine in a Phase 2A pilot study for mental fatigue.

Vistagen Therapeutics has commenced its PALISADE-3 Phase 3 trial for fasedienol, a novel nasal spray for the acute treatment of social anxiety disorder, following positive results from the PALISADE-2 study.

Vistagen Therapeutics announced its fiscal year 2024 third quarter financial results and provided a corporate update, highlighting progress in its clinical programs.